Celltrion has secured marketing authorisation from the European Commission (EC) for Avtozma (CT-P47), a biosimilar to Chugai ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a biosimilar referencing RoActemra® (tocilizumab). Avtozma® has been approved for ...

South Korean pharmaceutical firm Celltrion announced Monday that Avtozma, a biosimilar of Actemra, has received approval from the European Commission. The approval covers major indications of the ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma ® (CT-P47), a biosimilar referencing RoActemra ® (tocilizumab). Avtozma ® has been ...

According to Celltrion, the biosimilar for ACTEMRA, "AVTOZMA," has been approved for major treatment diseases of original drugs such as rheumatoid arthritis (RA) and giant cell arteritis (GCA).

Celltrion, a major South Korean biopharmaceutical firm, on Monday said its new biosimilar for an autoimmune disease treatment ha ...

The EC approved Celltrion's Avtozma, a biosimilar to Actemra, in both intravenous and subcutaneous formulations, for sales in the member countries of the European Union, the company said in a ...